Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Hypertension. 2014 Jul 7;64(4):852–859. doi: 10.1161/HYPERTENSIONAHA.114.03848

Figure 4. Working model.

Figure 4

Conceptualized time-course for the development of maximal plasma concentrations of copeptin (and thus vasopressin release), markers and mediators of immune function, vascular function, angiogenesis and clinical symptoms of preeclampsia. We posit that the hypersecretion of AVP in the first trimester is an initiator of other previously-identified mediators of preeclampsia, which are known to become more active later in pregnancy.